Alchemab Therapeutics has entered into a licensing agreement with Eli Lilly and Company for ATLX-1282, Alchemab's first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. The deal worth up to $415m includes an undisclosed upfront payment, potential discovery, development, and commercialisation payments, and royalties. Alchemab will take the programme through early Phase 1 clinical trials, after which Lilly will lead all further development and commercialisation.
Company Information
Company
Alchemab Therapeutics
Location
London, England, United Kingdom
About
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development.
Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies.
Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.
LondonBiotechnologyHealth CareTherapeuticsPharmaceutical